Shanghai Fosun Pharmaceutical (600196.SH): Compound Polyethylene Glycol (3350) Electrolyte Powder Approved for Registration
Fosun Pharma (600196.SH) announced that its holding subsidiary, Suzhou Erye Pharmaceutical Co., Ltd., has recently received approval from the National Medical Products Administration for its drug registration application of Compound Polyethylene Glycol (3350) Electrolyte Powder. The approved indications are: (1) for the treatment of chronic constipation in children aged 1 to 11 years; (2) for the treatment of fecal impaction in children aged 5 to 11 years, specifically for stubborn constipation accompanied by rectal and/or colonic fecal mass accumulation.
Shanghai Fosun Pharmaceutical (600196.SH) announced that its holding subsidiary Suzhou Erye Pharmaceutical Co., Ltd. has recently received approval from the National Medical Products Administration for the drug registration application of Compound Polyethylene Glycol (3350) Electrolyte Powder. The approved indications are (1) for the treatment of chronic constipation in children aged 1 to 11 years; and (2) for the treatment of fecal impaction in children aged 5 to 11 years, which is severe constipation accompanied by rectal and/or colonic fecaloma accumulation.
The approval of this drug for market launch will further enrich the group's product line.
Related Articles
FUSEN PHARM (01652): Four products are expected to win bids in the national centralized drug procurement.
Shengda Resources (000603.SZ) subsidiary Honglin Mining has obtained the safety production license for the tailings pond.
EUROEYES (01846): Rens Laurentius Michal Schoenmakers has been appointed as Executive Director.
FUSEN PHARM (01652): Four products are expected to win bids in the national centralized drug procurement.
Shengda Resources (000603.SZ) subsidiary Honglin Mining has obtained the safety production license for the tailings pond.
EUROEYES (01846): Rens Laurentius Michal Schoenmakers has been appointed as Executive Director.
RECOMMEND
